New challenges in lower urinary tract and pelvic floor disorders

Sender Herschorn, MD, FRCSC

Professor, Division of Urology, University of Toronto, and Head of Urodynamics Laboratory, Sunnybrook Health Sciences Centre, Toronto, ON

Cite as: Can Urol Assoc J 2013;7(9-10):S169. http://dx.doi.org/10.5489/cuaj.1612 Published online October 9, 2013.

he 3rd Annual Canadian Urology Forum (2013) focused on the workup and management of patients with challenging presentations of lower urinary tract (LUT) and pelvic floor disorders. The educational sessions brought together a distinguished panel of international and Canadian opinion leaders, and involved extensive discussion and interaction among the faculty and participants.

The overall learning objectives of the 2013 forum were to:

- 1. Recognize possible causes of treatment failure in patients with overactive bladder (OAB);
- 2. Identify systemic and financial barriers to the successful treatment of voiding dysfunction and determine strategies to overcome them;
- Evaluate evidence for new therapies to treat LUT and pelvic floor disorders and assess their clinical applications;
- Develop an individualized management approach to LUT and pelvic floor disorders occurring in special patient populations;
- 5. Consider post-prostatectomy complications or pelvic floor disorders in relation to their effects on patient health, quality of life and treatment options; and
- Describe the features and management of painful bladder syndrome.

To that end, the faculty were asked to cover six individual sub-topics. Drs. Sender Herschorn and Alan Wein presided over the session reviewing current challenges in OAB. Drs. Cornelius Kelleher, Sidney Radomski, Jane Schulz and Karl-Erik Andersson followed with a session examining current and future treatment considerations for lower urinary tract symptoms (LUTS) and pelvic floor disorders.

Selected special populations were the focus of the third session, with Dr. Jacques Corcos reviewing the management of voiding dysfunction in patients with multiple sclerosis, and Dr. Cara Tannenbaum discussing the management of LUTS in frail elderly patients.

The Urology Forum participants then divided into two groups for the next portion of the program. The two concurrent sessions were: post-prostatectomy complications and pelvic floor disorders. In the former, the discussion was led by Drs. Greg Bailly, Sidney Radomski, Sender Herschorn and Michael Coburn. The latter group engaged in discussions led by Drs. Jane Schulz, Cornelius Kelleher, Catherine Flood and Rebecca Rogers.

During each sub-topic session, the faculty and participants interacted to discuss one or more case studies illustrating the key diagnostic and/or therapeutic challenges. The highlights of the presentations and discussions, including the case studies, are summarized in the following pages.

The 2013 Canadian Urology Forum was another successful educational event for those who attended. Our goal with this publication is to share the valuable information exchanged during the forum with other healthcare professionals in Canada and around the world.

Competing interests: This article is part of a CUAJ supplement sponsored by Astellas Pharma Canada, Inc. Dr. Herschorn is an ongoing paid consultant for, or has received speaker fees, educational grants, and/or travel assistance from Allergan, American Medical Systems, Astellas, Merus Labs, Pfizer, and Promedon.

Correspondence: Dr. Sender Herschorn, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Rm. A309, 2075 Bayview Ave., Toronto ON M4N 3M5; s.herschorn@utoronto.ca